By Amin Kef Sesay
Director-General Dr. Tedros Adhanom Ghebreyesus has disclosed that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments.
He said about 20 institutions and companies “are racing to develop a vaccine.”
Tedros said the WHO will be announcing an initiative soon for the accelerated development and equitable distribution of vaccines.
He reiterated that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments and “about 20 institutions and companies are racing to develop a vaccine.” “The viral genome was mapped in early January and shared globally which enabled tests to be developed and vaccine research to start,” Tedros said at a news conference at WHO headquarters in Geneva.
Dr. Mike Ryan, the WHO’s Executive Director for Emergencies Program, said one trial underway will look at prophylaxis in health-care workers to see if there’s evidence of giving lower doses of drugs like hydroxychloroquine that would reduce their risk of becoming infected while treating patients.
Tedros said the WHO will be announcing an initiative soon for the accelerated development and equitable distribution of vaccines.
“We will put together a mechanism and we will appoint senior people from the north and south that will work out the details of how they can accelerate production but at the same time how they can ensure equitable distribution,” he said. “When a vaccine or a medicine is ready, we have to be able to deliver it to all over the world. There should not be a divide between the haves and the have-nots.”
New York State last month began the first large-scale clinical trial looking at hydroxychloroquine as a possible treatment for the coronavirus after the Food and Drug Administration fast-tracked the approval process.
President Donald Trump has said chloroquine and hydroxychloroquine could be a “game-changer,” even though the drugs have not been put through rigorous clinical trials to fight CV-19, which has infected more than 1 million people worldwide in a little over three months. Trump last month directed the FDA to examine whether the drugs can be used to prevent or treat the coronavirus.
Chloroquine has gained a lot of attention after a small study of 36 COVID-19 patients published March 17 in France found that most patients taking the drug cleared the coronavirus from their system a lot faster than the control group. Adding azithromycin, commonly known as a Z-Pak, to the mix “was significantly more efficient for virus elimination,” the researchers said. A small study in China also found that combining chloroquine with azithromycin was “found to be more potent than chloroquine.”
WHO said early research showed that some drugs “may have an impact” on fighting the coronavirus, but the data are extremely preliminary and more research needs to be done to determine whether the treatments can reliably fight COVID-19.
There is “some preliminary data from non-randomized studies, observational studies that indicate some drugs and some drug cocktails may have an impact,” Ryan said.
“Some of those drugs may impact the length of disease, some may impact the severity of disease and the dosages of those drugs when they’re given to what patient at what stage of the disease has not been standardized,” Ryan said. “We have never had a comparison group where we’ve had a randomized approach to treatment with the drug or not treatment with the drug.”
“So that we’re clear there’s no proven effective therapeutic or drug against COVID-19,” he added.
